Wildtype and A30P mutant alpha-synuclein form different fibril structures.
Parkinson's Disease (PD) is a neurodegenerative movement disorder affecting millions of people worldwide. One of the key players in the development of the disease is the protein α-synuclein (aSN), which aggregates in the brain of PD patients. The aSN mutant A30P has been reported to cause early...
Main Authors: | Søren Bang Nielsen, Francesca Macchi, Samuele Raccosta, Annette Eva Langkilde, Lise Giehm, Anders Kyrsting, Anna Sigrid Pii Svane, Mauro Manno, Gunna Christiansen, Niels Christian Nielsen, Lene Oddershede, Bente Vestergaard, Daniel Erik Otzen |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS ONE |
Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23861789/pdf/?tool=EBI |
Similar Items
-
Release of Pharmaceutical Peptides in an Aggregated State: Using Fibrillar Polymorphism to Modulate Release Levels
by: Jens K. Madsen, et al.
Published: (2019-03-01) -
Reducing the Amyloidogenicity of Functional Amyloid Protein FapC Increases Its Ability To Inhibit α‑Synuclein Fibrillation
by: Line Friis Bakmann Christensen, et al.
Published: (2019-02-01) -
Two conformationally distinct α-synuclein oligomers share common epitopes and the ability to impair long-term potentiation.
by: Femke van Diggelen, et al.
Published: (2019-01-01) -
The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma
by: Bill H. Diplas, et al.
Published: (2018-05-01) -
Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
by: Sara E Gombash, et al.
Published: (2013-01-01)